|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
DE68928427T2
(de)
|
1988-09-15 |
1998-06-04 |
Univ Columbia |
Antikörper mit modifiziertem Kohlenhydratgehalt und Verfahren zur Herstellung und Verwendung
|
|
JP2650358B2
(ja)
|
1988-10-06 |
1997-09-03 |
株式会社ニコン |
半透過部材を有する光学装置
|
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
|
CA2018248A1
(en)
|
1989-06-07 |
1990-12-07 |
Clyde W. Shearman |
Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
CA2126967A1
(en)
|
1992-11-04 |
1994-05-11 |
Anna M. Wu |
Novel antibody construct
|
|
US5792456A
(en)
*
|
1994-08-04 |
1998-08-11 |
Bristol-Myers Squibb Company |
Mutant BR96 antibodies reactive with human carcinomas
|
|
PT706799E
(pt)
|
1994-09-16 |
2002-05-31 |
Merck Patent Gmbh |
Imunoconjugados ii
|
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
WO1996040662A2
(en)
*
|
1995-06-07 |
1996-12-19 |
Cellpro, Incorporated |
Aminooxy-containing linker compounds and their application in conjugates
|
|
US5989830A
(en)
|
1995-10-16 |
1999-11-23 |
Unilever Patent Holdings Bv |
Bifunctional or bivalent antibody fragment analogue
|
|
GB9524973D0
(en)
|
1995-12-06 |
1996-02-07 |
Lynxvale Ltd |
Viral vectors
|
|
SE9601245D0
(sv)
|
1996-03-29 |
1996-03-29 |
Pharmacia Ab |
Chimeric superantigens and their use
|
|
US6254868B1
(en)
*
|
1996-03-20 |
2001-07-03 |
Immunomedics, Inc. |
Glycosylated humanized B-cell specific antibodies
|
|
AU3968897A
(en)
|
1996-08-02 |
1998-02-25 |
Bristol-Myers Squibb Company |
A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
CA2307166A1
(en)
*
|
1997-10-31 |
1999-05-14 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
|
US6953675B2
(en)
|
1997-11-06 |
2005-10-11 |
Immunomedics, Inc. |
Landscaped antibodies and antibody fragments for clinical use
|
|
US6001817A
(en)
*
|
1998-01-12 |
1999-12-14 |
Unitech Pharmaceuticals, Inc. |
Pharmaceutical composition comprised of cisplatin, and processes for making and using same
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
CA2323757C
(en)
|
1998-04-02 |
2011-08-02 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
JP2002522063A
(ja)
|
1998-08-17 |
2002-07-23 |
アブジェニックス インコーポレイテッド |
増加した血清半減期を有する改変された分子の生成
|
|
EP1115740A1
(en)
|
1998-09-23 |
2001-07-18 |
The Regents of the University of California |
Synthetic peptides, conjugation reagents and methods
|
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
HUP0104865A3
(en)
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
|
US20020102208A1
(en)
|
1999-03-01 |
2002-08-01 |
Paul Chinn |
Radiolabeling kit and binding assay
|
|
CN1110322C
(zh)
*
|
1999-07-21 |
2003-06-04 |
中国医学科学院医药生物技术研究所 |
单克隆抗体Fab'－平阳霉素偶联物及其抗肿瘤作用
|
|
AU2001270609A1
(en)
|
2000-06-30 |
2002-01-14 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Heterodimeric fusion proteins
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
|
US20050107595A1
(en)
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
AU2002368077B2
(en)
|
2001-07-12 |
2010-03-04 |
Jefferson Foote |
Super humanized antibodies
|
|
US6900292B2
(en)
|
2001-08-17 |
2005-05-31 |
Lee-Hwei K. Sun |
Fc fusion proteins of human erythropoietin with increased biological activities
|
|
US7173003B2
(en)
*
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
|
US7696163B2
(en)
*
|
2001-10-10 |
2010-04-13 |
Novo Nordisk A/S |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
EP2292273A3
(en)
*
|
2001-10-10 |
2011-11-23 |
BioGeneriX AG |
Remodeling and glycoconjugation of peptides
|
|
US7265084B2
(en)
*
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
|
US7214660B2
(en)
*
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
US7226903B2
(en)
*
|
2001-10-10 |
2007-06-05 |
Neose Technologies, Inc. |
Interferon beta: remodeling and glycoconjugation of interferon beta
|
|
US7795210B2
(en)
*
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
|
EA008220B1
(ru)
|
2001-10-29 |
2007-04-27 |
Круселл Холланд Б.В. |
Композиция, включающая эритропоэтинподобные молекулы, и способы ее применения
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US20040018557A1
(en)
|
2002-03-01 |
2004-01-29 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20070207142A1
(en)
*
|
2002-05-08 |
2007-09-06 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
|
PT1534335E
(pt)
|
2002-08-14 |
2012-02-28 |
Macrogenics Inc |
Anticorpos específicos de fcγriib e processos para a sua utilização
|
|
CA2832136C
(en)
|
2002-09-27 |
2015-11-17 |
Xencor |
Optimized fc variants and methods for their generation
|
|
ATE480562T1
(de)
|
2002-10-15 |
2010-09-15 |
Facet Biotech Corp |
Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
|
|
US7355008B2
(en)
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
CA2522345A1
(en)
*
|
2003-04-09 |
2004-11-18 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
|
ES2371072T3
(es)
|
2003-06-12 |
2011-12-27 |
Eli Lilly And Company |
Proteínas de fusión análogas de glp-1.
|
|
AU2004266159A1
(en)
|
2003-08-22 |
2005-03-03 |
Biogen Idec Ma Inc. |
Improved antibodies having altered effector function and methods for making the same
|
|
RU2392324C2
(ru)
|
2003-09-18 |
2010-06-20 |
Симфоген А/С |
Способ связывания интересующих последовательностей
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
ES2605443T3
(es)
*
|
2003-11-06 |
2017-03-14 |
Seattle Genetics, Inc. |
Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
|
|
WO2005047327A2
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
|
|
US7001978B2
(en)
|
2003-11-19 |
2006-02-21 |
Xerox Corporation |
Unsaturated ester substituted polymers with reduced halogen content
|
|
JP2007512846A
(ja)
|
2003-12-04 |
2007-05-24 |
ゼンコー・インコーポレイテッド |
増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
|
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
|
NZ548123A
(en)
*
|
2004-01-08 |
2010-05-28 |
Novo Nordisk As |
O-linked glycosylation of peptides
|
|
JP4762156B2
(ja)
|
2004-01-12 |
2011-08-31 |
アプライド モレキュラー エボリューション，インコーポレイテッド |
Ｆｃ領域変異体
|
|
US7276585B2
(en)
|
2004-03-24 |
2007-10-02 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
CA2565414A1
(en)
|
2004-05-04 |
2005-11-24 |
Novo Nordisk Health Care Ag |
O-linked glycoforms of polypeptides and method to manufacture them
|
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
EP3342782B1
(en)
|
2004-07-15 |
2022-08-17 |
Xencor, Inc. |
Optimized fc variants
|
|
TR201808537T4
(tr)
*
|
2004-09-23 |
2018-07-23 |
Genentech Inc |
Sistein değiştirilmiş antikorlar ve konjugatlar.
|
|
EP1799700A4
(en)
|
2004-09-27 |
2009-02-11 |
Centocor Inc |
SRAGE MIMETIC BODIES, COMPOSITIONS, PROCESSES AND USES
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
JP4829609B2
(ja)
|
2004-12-22 |
2011-12-07 |
独立行政法人科学技術振興機構 |
ヒト抗体酵素およびその生産方法
|
|
US8217154B2
(en)
|
2005-02-23 |
2012-07-10 |
Lipoxen Technologies Limited |
Activated sialic acid derivatives for protein derivatisation and conjugation
|
|
JP5238936B2
(ja)
|
2005-03-25 |
2013-07-17 |
ジーアイティーアール，インク． |
Ｇｉｔｒ結合分子およびその使用
|
|
JP2008537941A
(ja)
*
|
2005-03-31 |
2008-10-02 |
ゼンコー・インコーポレイテッド |
最適化特性を有するＦｃ変異体
|
|
AU2006230413B8
(en)
|
2005-03-31 |
2011-01-20 |
Xencor, Inc |
Fc variants with optimized properties
|
|
WO2006130834A2
(en)
|
2005-05-31 |
2006-12-07 |
Board Of Regents, The University Of Texas System |
IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
|
|
ES2547463T3
(es)
|
2005-06-17 |
2015-10-06 |
Merck Sharp & Dohme Corp. |
Moléculas de unión a ILT3 y usos de las mismas
|
|
CN101506238B
(zh)
|
2005-06-30 |
2013-11-06 |
森托科尔公司 |
具有提高治疗活性的方法和成分
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
US7846724B2
(en)
|
2006-04-11 |
2010-12-07 |
Hoffmann-La Roche Inc. |
Method for selecting CHO cell for production of glycosylated antibodies
|
|
AU2007319672B2
(en)
*
|
2006-06-06 |
2011-06-30 |
Genentech, Inc. |
Anti-DLL4 antibodies and methods using same
|
|
WO2008094176A2
(en)
|
2006-06-19 |
2008-08-07 |
Tolerx, Inc. |
Ilt3 binding molecules and uses therefor
|
|
WO2007149870A2
(en)
*
|
2006-06-19 |
2007-12-27 |
The Regents Of The University Of California |
Two-color fluorescent reporter for alternative pre-mrna splicing
|
|
US8460362B2
(en)
|
2006-07-20 |
2013-06-11 |
Orbusneich Medical, Inc. |
Bioabsorbable polymeric medical device
|
|
CN101516388B
(zh)
*
|
2006-07-21 |
2012-10-31 |
诺和诺德公司 |
通过o-联糖基化序列的肽的糖基化
|
|
WO2008060780A2
(en)
|
2006-10-04 |
2008-05-22 |
Novo Nordisk A/S |
Glycerol linked pegylated sugars and glycopeptides
|
|
FI20060946A0
(fi)
*
|
2006-10-26 |
2006-10-26 |
Glykos Finland Oy |
Influenssaviruksen nukleiinihappoja ja peptidejä
|
|
JP2010512306A
(ja)
*
|
2006-10-27 |
2010-04-22 |
ザ ロックフェラー ユニバーシティー |
抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法
|
|
PE20081250A1
(es)
|
2006-11-28 |
2008-10-07 |
Centelion |
FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
|
|
GEP20125693B
(en)
|
2007-01-09 |
2012-11-26 |
Biogen Idec Inc |
Sp35 antibodies and usage thereof
|
|
CA2669412A1
(en)
|
2007-01-23 |
2008-07-31 |
Xencor, Inc. |
Optimized cd40 antibodies and methods of using the same
|
|
PE20090245A1
(es)
|
2007-05-08 |
2009-03-17 |
Genentech Inc |
Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
|
|
US20100260751A1
(en)
*
|
2007-09-28 |
2010-10-14 |
Raju T Shantha |
Methods and Structural Conformations of Antibody Preparations with Increased Resistance to Proteases
|
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
|
BRPI0818780A2
(pt)
|
2007-10-19 |
2015-04-22 |
Genentech Inc |
Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
|
|
CN102037004A
(zh)
*
|
2008-01-08 |
2011-04-27 |
生物种属学股份公司 |
使用寡糖基转移酶的多肽的糖缀合
|
|
DK2657253T3
(en)
*
|
2008-01-31 |
2017-10-09 |
Genentech Inc |
Anti-CD79b antibodies and immune conjugates and methods of use
|
|
EP2268807A2
(en)
|
2008-04-21 |
2011-01-05 |
Novo Nordisk A/S |
Hyperglycosylated human coagulation factor ix
|
|
UA40611U
(ru)
|
2008-05-26 |
2009-04-27 |
Владимир Семенович Живченко |
Способ десульфурации железоуглеродистого расплава в тигельной печи
|
|
CA2735193A1
(en)
|
2008-08-26 |
2010-03-11 |
Macrogenics, Inc. |
T-cell receptor antibodies and methods of use thereof
|
|
EP2233499A1
(en)
|
2009-03-26 |
2010-09-29 |
CSL Behring AG |
Antibody composition with altered Fab sialylation
|
|
US10087236B2
(en)
*
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
US9234192B2
(en)
|
2010-02-16 |
2016-01-12 |
Novo Nordisk A/S |
Conjugated proteins
|
|
DK2542256T3
(da)
|
2010-03-04 |
2019-08-26 |
Macrogenics Inc |
Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
|
|
EP2603528B1
(en)
*
|
2010-08-10 |
2016-10-12 |
Glycotope GmbH |
Fab-glycosylated antibodies
|
|
WO2012125402A2
(en)
|
2011-03-11 |
2012-09-20 |
Amicus Therapeutics, Inc. |
Dosing regimens for the treatment of fabry disease
|
|
AR085302A1
(es)
*
|
2011-02-24 |
2013-09-18 |
Sanofi Sa |
Metodo de produccion de anticuerpos sialilados
|
|
TWI622597B
(zh)
|
2011-03-28 |
2018-05-01 |
賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
|
US9790268B2
(en)
*
|
2012-09-12 |
2017-10-17 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
|
FI3366705T3
(fi)
|
2012-09-12 |
2023-07-28 |
Genzyme Corp |
Muuttuneen glykosylaation ja vähentyneen efektoritoiminnan omaavia fc:n sisältäviä polypeptidejä
|
|
US9580511B2
(en)
|
2013-03-11 |
2017-02-28 |
Genzyme Corporation |
Site-specific antibody-drug conjugation through glycoengineering
|
|
HUE061339T2
(hu)
|
2014-03-19 |
2023-06-28 |
Genzyme Corp |
Targetáló csoportok helyspecifikus glikotechnikai átalakítása
|
|
ES3060461T3
(en)
|
2014-04-08 |
2026-03-26 |
Univ Georgia |
Site-specific antibody-drug glycoconjugates and methods
|
|
PL3204425T3
(pl)
*
|
2014-10-09 |
2021-03-08 |
Genzyme Corporation |
Glikomodyfikowane koniugaty przeciwciał z lekami
|
|
JP7575401B2
(ja)
|
2019-04-03 |
2024-10-29 |
ジェンザイム・コーポレーション |
断片化が低減した抗アルファベータｔｃｒ結合ポリペプチド
|